Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Temporal trends in Burkitt lymphoma–related mortality in the United States over the last three decades: An analysis of the Global Burden of Disease database.

Ahmed A. Abdulelah, Zaid Zahid, Majd Albarjak et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19074

e19074 Background: Burkitt lymphoma (BL) is a rare but aggressive form of non-Hodgkin lymphoma, with significant mortality implications in the United Stat...

Tumor proportion score (TPS) and response to first-line (1L) anti–PD-1/PD-L1 plus chemotherapy for metastatic non-small cell lung cancer (NSCLC): A real-world cohort study.

Imi Faghmous, Antonio Nicoale, Parameswaran N Hari et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20606

e20606 Background: The efficacy of chemotherapy combined with PD-1/PD-L1 inhibitors (CIO) in metastatic NSCLC is influenced by PD-L1 expression levels. De...

Venetoclax/azacitidine vs intensive chemotherapy as a bridge to allogeneic HSCT in AML: Experience from Ukraine.

Oleksandr Istomin, Olha Veremiychyk, Oleksandr Lysytsia Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18539

e18539 Background: Allogeneic stem cell transplantation (alloSCT) is the curative standard for high- and intermediate-risk acute myeloid leukemia (AML). H...

Development and validation of an AI model for predicting germline BRCA1/2 mutations from HR+/HER2- breast cancer histology images.

Oussama Tchita, Elin Samuelsson, Ingrid Garberis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13611

e13611 Background: Pathogenic germline BRCA1/2 mutations (g BRCA mut) are critical biomarkers in breast ca...

Is increase in CME consumption associated with practice change in the real world? An empirical study among oncologists treating breast cancer.

Katie Lucero, Jordan Schwartz, Urvi Patel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23284

e23284 Background: Online medical information is important for oncologists to stay current in practice. A worldwide survey of oncologists (n = 57; 54% US)...

Characterization of CLDN18 expression in a Western biliary tract cancer population.

Alexander Bray, Jiaqi Shi, Chandan kumar et al. Jun 01, 2025 pp. 4089-4089 10.1200/jco.2025.43.16_suppl.4089

4089 Background: Patients with advanced biliary tract cancer (BTC) have poor survival despite recent advances in chemoimmunotherapy. Claudin 18 (CLDN18) d...

Navigating neutropenia in oncology: Insights into clinical characteristics and outcomes from a Brazilian clinic.

Caio de Jesus, Audrey Cabral Ferreira de Oliveira, Isadora Mamede et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24090

e24090 Background: Neutropenia is a frequent adverse event associated with antineoplastic agents, yet real-world data during the COVID pandemic remains sc...

Patient satisfaction with telehealth as an element of hybrid decentralized clinical trials (DCTs): A cross-sectional study of oncology clinical trial participants.

Andrew Ohyama Parsonson, Deme John Karikios, John J. Park et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13884

e13884 Background: Decentralized elements (DEs) of clinical trials (CTs) such as Telehealth (TH) allow some trial related activities to occur without requ...

Long-term off-label MAPK inhibitor therapy in children with severe/refractory Langerhans cell histiocytosis: An international observational study of 277 cases.

Jean Donadieu, Dmitry Evseev, Caroline Hutter et al. Jun 01, 2025 pp. 10011-10011 10.1200/jco.2025.43.16_suppl.10011

10011 Background: Long-term off-label use of MAP kinase inhibitors (MAPKi) to treat, refractory childhood Langerhans cell histiocytosis (LCH) was evaluate...

Evaluating survivorship-related communication gaps to develop a community health worker-led intervention for Hispanic/Latino young adult childhood cancer survivors and their families.

Stephanie M. Smith, Briana Cristal Martin-Villa, Kevin Shanchen Pu et al. Jun 01, 2025 pp. 10072-10072 10.1200/jco.2025.43.16_suppl.10072

10072 Background: Open communication among young adult childhood cancer survivors (YA-CCS), parents, and clinicians helps YA-CCS understand their cancer h...

Impact of cell of origin, gene rearrangements, and frontline treatment on incidence of secondary central nervous system lymphoma in newly diagnosed diffuse large B-cell lymphoma.

Ayo Samuel Falade, Raphael Mwangi, Paul Joseph Hampel et al. Jun 01, 2025 pp. 7052-7052 10.1200/jco.2025.43.16_suppl.7052

7052 Background: Secondary central nervous system lymphoma (SCNSL) is a rare but serious complication that occurs in 2-10% of patients (pts) with diffuse...

Effects of setup margin and biology tracking zone variations on dosimetric plan quality and treatment feasibility in biology-guided radiotherapy for bone metastasis.

Chunhui Han, Grant Gibbard, Yi-Jen Chen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15107

e15107 Background: In biology-guided radiotherapy (BgRT), real-time positron emission tomography (PET) signals are used to guide radiation beams to F-18 f...

Real-world clinical outcomes of patients with BRAF-mutated melanoma with or without brain metastases receiving frontline immune-checkpoint inhibitors in the US community oncology setting.

Wolfram Samlowski, Andrew J. Osterland, Lisa Herms et al. Jun 01, 2025 pp. 9542-9542 10.1200/jco.2025.43.16_suppl.9542

9542 Background: Patients with BRAF-mutated melanoma are at increased risk of melanoma brain metastasis (MBM) which has historically led to worse outcomes...

Health-related social needs and mortality risk among United States Veterans with non-small cell lung cancer.

Steven Tohmasi, Daniel B. Eaton, Nikki E. Rossetti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13750

e13750 Background: Multiple expert bodies recognize screening and referrals for health-related social needs (HRSNs) as vital components of comprehensive a...

Characterization of copy number variations (CNV) patterns and pseudotime trajectories in high-grade serous ovarian cancer (HGSOC).

Luca Mastrantoni, Federica Persiani, Floriana Camarda et al. Jun 01, 2025 pp. 5595-5595 10.1200/jco.2025.43.16_suppl.5595

5595 Background: HGSOC is characterized by genomic instability, resulting in frequent CNVs. This study aimed to characterize CNV patterns and derive pseud...

Melatonin for alleviating cancer-related fatigue in cancer patients.

Sugam Gouli, Zauraiz Anjum, Aliza Dulal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24047

e24047 Background: Cancer-related fatigue is a common symptom among patients with cancer and is debilitating, significantly impacting their quality of lif...

Evaluating the effectiveness of treatment cost calculation tool in improving patients' understanding of drug costs in advanced breast cancer: A multicenter, randomized controlled trial.

Kosho Yamanouchi, Sayaka Kuba, Hiroki Moriuchi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13566

e13566 Background: In breast cancer, the prognosis has improved with the introduction of new drugs; however, due to their high cost, patients are facing i...

Partnering with patients to deliver window-of-opportunity clinical trials in immuno-oncology.

Carol Gordon, Emily Mcintosh, Rebecca J. Rose et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23023

e23023 Background: Oncologic drug development is costly and protracted, often exceeding $2 billion USD and spanning over a decade. Window-of-Opportunity (...

Examining factors affecting clinical trial enrolment in the Clinical Trials Navigator program.

Michael Touma, Govana Sadik, Renée Nassar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23143

e23143 Background: Oncology clinical trial accrual rates are estimated to be around 5%, despite the potential benefits patients could receive on a clinica...

Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases.

Elmira Forouzmand, Yupeng He, William Young Greenwald et al. Jun 01, 2025 pp. 3073-3073 10.1200/jco.2025.43.16_suppl.3073

3073 Background: Cancer of unknown primary (CUP) lacking resolution to a cancer type (Cancer Signal Origin; CSO) leads to...

Clinical characteristics and treatment outcomes of colorectal cancer in a resource-restricted country.

Sarah Abdel-Razeq, Asem Mansour, Maha Barbar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15723

e15723 Background: Colorectal cancer is the second most common cancer in Jordan and remains the second common cancer-related deaths in both men and women....

Enhancing clinical trial screening with a comprehensive large language model platform.

Jai Narendra Patel, Michael Cyrus Maher, Robyn Yano et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13674

e13674 Background: Clinical trials are essential for improving cancer treatment; yet 80% of trials fail to meet enrollment timelines, often due to ineffic...

A case-based learning program in medical oncology: A trainee-led feasibility study.

Jonathon William Vundum, Fiona Day Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21012

e21012 Background: Case-based learning (CBL) is widely used in undergraduate medical education, with demonstrable benefits for trainees across multiple do...

Concordance of somatic whole exome sequencing and germline genotyping of DPYD to screen for DPD deficiency.

Aditya Sharma, Donald Green, Wahab A. Khan et al. Jun 01, 2025 pp. 10584-10584 10.1200/jco.2025.43.16_suppl.10584

10584 Background: Fluoropyrimidines are amongst the most commonly used chemotherapeutic agents in the treatment of gastrointestinal and breast malignancie...

Identifying genetic susceptibility for severe cardiac events in testicular cancer survivors.

Arkajyoti Bhattacharya, Ellen Laura Dorien Volders, Sjoukje Lubberts et al. Jun 01, 2025 pp. 12048-12048 10.1200/jco.2025.43.16_suppl.12048

12048 Background: Testicular cancer (TC) survivors face an increased risk of cardiovascular diseases (CVD) as a late adverse effect of oncological treatme...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page